Back to News

Latigo Biotherapeutics prices $345.6M IPO at $18 per share

No readable financial news content was provided (article text appears to be missing or only shows “403”), so no themes, sentiment, or market impact can be reliably extracted.

Analysis

No readable financial news content was provided (article text appears to be missing or only shows “403”), so no themes, sentiment, or market impact can be reliably extracted.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request Demo

Market Sentiment

Overall Sentiment

neutral

Sentiment Score

0.00

More News